PR Newswire Clinical TrialsOriginal article
Akeso Announces Opening of Global Phase II Study of Ivonescimab in First-Line Clear Cell Renal Cell Carcinoma, Including Combination with Cadonilimab
Trial StartIvonescimabCadonilimabPositive
AI Analysis
Summary
Akeso and partner Summit Therapeutics announced the opening of an international multicenter Phase II study (SMT112-216 / AK112-216 / NCT07877194) of ivonescimab in first-line clear cell renal cell carcinoma, including a combination with cadonilimab.
Clinical Trial Data
Phase
Phase_2
NCT ID
Outcome Details
Opening of an international multicenter Phase II study of ivonescimab, including a combination arm with cadonilimab, in first-line clear cell RCC.
Importance:4/10
Sentiment:
0.30
ivonescimabcadonilimabrenal cell carcinomaPhase 2trial startoncologyAkesoSummit Therapeuticsimmuno-oncology
Read the original article
Published by PR Newswire Clinical Trials on October 19, 2026 11:59 AM